Schrödinger (NASDAQ: SDGR) Stock Analysis: Performance, Ratings, and Financial Outlook

• Cowen & Co. maintains a Buy rating on Schrödinger (NASDAQ: SDGR) stock, which is currently trading at $25.91.
• Schrödinger shows significant price movements, with its shares trading above GuruFocus's estimated GF Value of $24.08.
• Schrödinger co-founded Tectora with $55 million in funding, while analysts project a $0.66 loss per share and $46.02 million in revenue for its next report.

Schrödinger (NASDAQ: SDGR) develops cutting-edge software that helps researchers model molecules and accelerate drug discovery. Cowen & Co. maintains a Buy rating on the biotech stock, which trades at $25.91 when the update is posted. A Buy rating means the analyst expects the shares to perform well, but it does not guarantee a gain.

At $25.91, Schrödinger is down $1.37, or 5.02%, for the day. It trades between $25.41 and $27.51 during the session, with 2.15 million shares changing hands. Its market value is about $1.94 billion, and its 52-week range is $10.95 to $33.78, reflecting its volatile stock performance.

Other price reports show how sharply Schrödinger can move. As highlighted by GuruFocus, the shares rise 3.4% to $27.28 on October 9, 2026. That price is 13.3% above GuruFocus’s estimated GF Value of $24.08, a benchmark for what the stock may be worth. GuruFocus also assigns Schrödinger a GF Score of 72 out of 100, offering valuable investment insights.

Schrödinger also closes one reported session up 7.6% at $32.60 after announcing that it co-founds Tectora with New Enterprise Associates and RA Capital Management. Tectora has $55 million in initial funding to develop treatments for immune and inflammatory conditions, showcasing Schrödinger's strategic expansion in biopharmaceutical development. As highlighted by Zacks Investment Research, analysts expect Schrödinger’s next report to show a $0.66 loss per share and $46.02 million in revenue, providing a glimpse into its financial projections.